CCM
HRTX icon

Consonance Capital Management’s Heron Therapeutics HRTX Stock Holding History

Consonance Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,005,218
Closed -$29.7M – 41
2020
Q3 		$29.7M Buy
+2,005,218
New +$31.3M 3.62% 14

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Consonance Capital Management's HRTX Position: Q4 2020 in Review

Consonance Capital Management sold out of Heron Therapeutics (HRTX) in Q4 2020, closing a stake of 2,005,218 shares — an estimated $29.7M sold.

Consonance Capital Management first reported a position in HRTX in Q3 2020 and held it in 1 quarter. The position peaked at $29.7M in Q3 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

  • Consonance Capital Management reported no remaining Heron Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Consonance Capital Management sold 2,005,218 Heron Therapeutics shares in Q4 2020, an estimated $29.7M.
  • Consonance Capital Management first reported a position in Heron Therapeutics in Q3 2020 and held it in 1 quarter.
  • Consonance Capital Management's Heron Therapeutics position peaked at $29.7M in Q3 2020.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.